DelMar Pharma presents positive preclinical data on VAL-083 for treatment of NSCLC
DelMar Pharmaceuticals announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer and as a potential combination therapy option in newly diagnosed NSCLC patients. April 19, 2015